ArticleOncoimmunology

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells.

Maria C Ochoa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.